Betta Pharmaceuticals Co., Ltd.
http://bettapharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Betta Pharmaceuticals Co., Ltd.
Merck’s Focus On ADCs Expands To Include Protein Degraders With C4
Deal snapshot: Viewing antibody-drug conjugates as a key to growing its cancer franchise beyond Keytruda, Merck & Co. will partner with C4 to develop protein degrader-antibody conjugates for cancer.
Asia Deal Watch: HanAll, Daewoong Team With US Biotech In Parkinson's
Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.
Oncology, Rare Disease Drugs Dominate New China Approvals
Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while a new biosimilar of a big seller moves into the spotlight.
Asia Deal Watch: Betta Will Bring Two Agenus Oncology Candidates To Its Market Area
Also, deals involving Immunomic, Replicate, Biocon, DKSH, Genor, G1, Daiichi Sankyo, Esperion, Alteogen, Gelesis, China Medical System Holdings, Sosei and EverInsight.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- AnewPharma Company, Ltd.
- Equinox Science, LLC
- Xcovery, Inc.
- Zhejiang Beta Pharma Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice